BIBLIOGRAFIA

1. American Diabetes Association: Implications of the United Kingdom Prospective Diabetes Study (Position Statement). Diabetes Care 23 (Suppl. 1):S27–S31, 2000

2. Andersson DKG, Svardsudd K: Long term glycemic control relates to mortality in type II diabetes. Diabetes Care 18 :1534–1543, 1995

3. The Diabetes Control and Complications Trial Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289–1298, 1996

4. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986, 1993

5. The Diabetes Control and Complications Trial Research Group: Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 276:1409–1415, 1996

6. The Diabetes Control and Complications Trial Research Group: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44 :968–983, 1995

7. Moss SE, Klein R, Klein BEK, Meuer MS: The association of glycemia and cause-specific mortality in a diabetic population. Arch Int Med 154:2473–2479, 1994

8. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyosyi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non–insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117, 1995

9. UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 :837–853, 1998

10. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 31: 703–713, 1998

11. Uusitupa MIJ, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K: Ten year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36:1174–1184, 1993